Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation

Stopped early · Phase 2

Conditions studied: Myelodysplastic Syndromes, Acute Myeloid Leukemia

In brief

This study will test the combination of clofarabine, cytarabine, and thymoglobulin as a non-myeloablative conditioning regimen for patients with myelodysplastic syndromes or acute myeloid leukemia undergoing allogeneic stem cell transplant.

Key facts

Study ID

NCT00593645

Run by

Washington University School of Medicine

People needed

7

Starts

2007-11-01

Expected to finish

2009-07-01

Last updated by the study team

2014-09-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Pregnant or nursing.
• Active systemic infection considered opportunistic, life threatening or clinically significant at the time of treatment.
• Severe concurrent disease, including severe insulin-dependent diabetes, uncontrolled hypertension, transient ischemic attacks, uncontrolled symptomatic coronary artery disease, or symptomatic CNS involvement or psychiatric illness/social situations that would limit compliance with study requirements.
• Known HIV disease.
• History of other malignancy except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast unless the subject has been off treatment and free from disease for > 3 years.
• Active disease at the time of transplant.

Where it is running

• Ravi Vij, M.D. — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.